静脉注射免疫球蛋白治疗难治性肌炎。

Intravenous immunoglobulin therapy for refractory myositis.

作者信息

Moriguchi M, Suzuki T, Tateishi M, Hara M, Kashiwazaki S

机构信息

Institute of Rheumatology, Tokyo Women's Medical College.

出版信息

Intern Med. 1996 Aug;35(8):663-7. doi: 10.2169/internalmedicine.35.663.

DOI:10.2169/internalmedicine.35.663

PMID:8894745

Abstract

The efficacy of polyvalent intravenous immunoglobulin therapy (IVIG) was evaluated in three patients with refractory myositis. Patients refractory to conventional therapy, such as corticosteroid administration, corticosteroid or cyclophosphamide pulse therapy [2 with dermatomyositis (DM), 1 with polymyositis (PM)] were treated with IVIG (0.4 g/kg daily) for 5 days. Clinical improvement was apparent within 1-2 months after IVIG and persisted for 19-23 months (DM patients) and 12 months (PM patient). No adverse effects were observed. Thus, IVIG may be considered an effective therapy for refractory myositis.

摘要

对三名难治性肌炎患者评估了多价静脉注射免疫球蛋白疗法（IVIG）的疗效。对常规治疗（如给予皮质类固醇、皮质类固醇或环磷酰胺冲击疗法）无效的患者（2例皮肌炎患者、1例多发性肌炎患者）接受了IVIG治疗（每日0.4 g/kg），持续5天。IVIG治疗后1 - 2个月内临床改善明显，且在皮肌炎患者中持续了19 - 23个月，在多发性肌炎患者中持续了12个月。未观察到不良反应。因此，IVIG可被视为难治性肌炎的一种有效治疗方法。